ROSECLIFF NEXT GENERATION LLC - SERIES CBIO ACCESS -1

Murphy's sole GP role with no prior EDGAR filings indicates a first-time fund manager launching into the market, which means the absence of historical performance data, carry precedent, or documented LP relationships creates heightened due diligence requirements around fund governance, operational infrastructure, and whether this vehicle has institutional co-GPs or advisors not captured in the named GP count.

A June 2026 filing under Rule 06b (pre-existing relationships only) in a biotech-focused fund aligns with LP appetite for direct or continuation exposure in life sciences post-2025 portfolio rebalancing cycles, though the zero close and small $10M target suggest this may be testing early interest rather than capitalizing on broad fundraising momentum.

Before committing, verify whether Series CBIO Access -1 is a placeholder filing tied to a larger successor fund in formation, confirm Murphy's operational team and whether a managing partner or chief investment officer sits above the named GP, and establish whether the fund intends to operate as a fully independent vehicle or as a feeder into a larger platform structure.